Ergoteles’s Core Laboratories CLB Stock Holding History

Ergoteles’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-35,899	Closed	-$792K	–	1103
2023 Q1	$792K	Buy	35,899 +19,737	+122%	+$462K	0.03%	581
2022 Q4	$328K	Sell	16,162 -2,438	-13%	-$47.3K	0.01%	878
2022 Q3	$251K	Buy	+18,600	New	+$313K	0.01%	1071
2021 Q4	–	Sell	-21,693	Closed	-$602K	–	1282
2021 Q3	$602K	Buy	+21,693	New	+$660K	0.02%	515

Other funds holding CLB

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Ergoteles's CLB Position: Q2 2023 in Review

Ergoteles sold out of Core Laboratories (CLB) in Q2 2023, closing a stake of 35,899 shares — an estimated $792K sold.

Ergoteles first reported a position in CLB in Q3 2021 and held it in 4 quarters. The position peaked at $792K in Q1 2023. 164 funds tracked by Wall St. Rank hold CLB as of Q2 2023.

Ergoteles reported no remaining Core Laboratories position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 35,899 Core Laboratories shares in Q2 2023, an estimated $792K.
Ergoteles first reported a position in Core Laboratories in Q3 2021 and held it in 4 quarters.
Ergoteles's Core Laboratories position peaked at $792K in Q1 2023.
164 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.